James Keaney
Company: Roche
Job title: Head of Lab, Research, Neuroimmunology & Project Leader
Seminars:
Elucidating the Potential of Bruton’s Tyrosine Kinase Inhibitors to Modulate Microglial Inflammation using Advanced 2D/3D Human Brain Cell Systems 8:00 am
Evaluating the functional and pharmacological properties of Fenebrutinib in blocking BTK-mediated disease-associated activation in human microglia and complex brain cell systems Fenebrutinib treatment attenuated pathogenic neuroinflammation associated with FcyR activation while preserving homeostatic innate immune cell functions This study increases understanding of potential BTK functions in human microglial signalling and neuroinflammation relevant to MS pathogenesisRead more
day: Conference Day Two